BPC-157's half-life is under 30 minutes in rats and dogs

What is the half-life of BPC-157?

BPC-157's elimination half-life is under 30 minutes in rats and beagle dogs, the only species in which it has been measured ^[7]. The figure comes from a 2022 pharmacokinetic study that tested intravenous and intramuscular administration at three ascending doses, with both single and repeated dosing ^[7].

The half-life of the intact peptide stayed under 30 minutes at every dose tested. Kinetics were linear across doses in both species, so BPC-157 did not accumulate or saturate its clearance pathways in a way that would change the half-life at higher doses ^[7].

The 2022 study meets the bar of a real pharmacokinetic study. It used serial blood sampling and standard modeling, the same methodology used in controlled human work on other short-half-life compounds such as the urodilatin infusion trial ^[2]. Its evidence grade is preclinical: a single study in two species.

What happens to BPC-157 after an injection?

After an intramuscular injection, 14 to 19 percent of a BPC-157 dose reaches the bloodstream intact in rats, and 45 to 51 percent in dogs ^[7]. A radiolabeled tracer in the same study showed the fate of the rest. BPC-157 broke down rapidly into small peptide fragments and then into single amino acids, which entered normal amino acid metabolism. Excretion ran through urine and bile ^[7].

Route of administration changes that picture. An intravenous injection produces a sharp peak and a fast decline. An intramuscular or subcutaneous injection creates a local depot that releases the compound into circulation more gradually, which changes both the peak concentration and how much of the dose reaches the bloodstream intact. Popular BPC-157 dosing guides rarely distinguish between routes when they repeat the half-life figure. The differences between intramuscular and subcutaneous injection are covered separately.

Has BPC-157's half-life been measured in humans?

No published study has measured BPC-157's half-life in humans. Nothing published has drawn human blood after a BPC-157 injection and modeled the clearance curve.

Rat and dog clearance does not automatically transfer to a person. Body size, enzyme activity, and injection technique differ across species. Anyone stating a human half-life for BPC-157, in either direction, is extrapolating past what has been measured, and no published study bridges rat and dog clearance rates to a person injecting subcutaneously at 11 p.m. after surgery.

A 2026 review of BPC-157's translational development flags the absence of any completed Phase II clinical trial and the lack of a validated human dosing regimen. The review describes a persistent gap between BPC-157's preclinical pharmacological activity and the pharmacokinetic data needed to support it ^[6]. What human research on BPC-157 does and does not show is covered separately.

Where does the 4 to 6 hour BPC-157 half-life figure come from?

The 4 to 6 hour figure has no identifiable published source. Clinic pages, podcasts, and forums repeat it, but it does not trace to any pharmacokinetic study, and the number underneath most twice-daily dosing charts does not match the only data set that exists ^[7].

The 2022 study notes that BPC-157 becomes essentially undetectable in plasma at some point after administration. That is a clearance observation, not a half-life measurement ^[7]. Clearance time and half-life are related but not interchangeable. A compound can take several half-lives to become undetectable, because its concentration keeps halving until it falls below the assay's sensitivity.

The origin of the 4 to 6 hour figure is undocumented. One explanation fits the discrepancy: a rough clearance window, reported informally as a "half-life" in vendor materials or forum summaries and then copied forward without a check against the paper.

Why do peptides like BPC-157 clear so quickly?

Small peptides generally clear from plasma in minutes rather than hours, because blood is full of enzymes built to cut short amino acid chains apart. Once a peptide loses its intact structure, it generally stops behaving like the original molecule, even if fragments or free amino acids remain detectable afterward.

Single-digit-minute half-lives are common among peptide-based compounds. In one controlled human infusion trial, the peptide hormone urodilatin cleared with an elimination half-life of about 5.6 minutes ^[2]. BPC-157's half-life of under 30 minutes in rats and dogs also falls in minutes, not hours ^[7].

How is half-life different from how long BPC-157 lasts?

Elimination half-life is the time BPC-157's plasma concentration takes to fall by half, assuming first-order kinetics, not how long the peptide lasts. Half-life is a different measurement from how long a drug stays detectable or how long its effect takes to wear off. Conflating those measurements is the error that has propagated through BPC-157 dosing advice.

In conventional drug dosing, clinicians typically wait roughly four to five half-lives for a compound to reach steady state or clear the body. Human antibiotic pharmacokinetics illustrates the convention: "more than four half-lives" is the standard threshold used to define steady-state sampling ^[5]. The principle is general pharmacology, not a BPC-157 finding, but it shows why the distinction matters. If BPC-157's half-life is 30 minutes, four half-lives is two hours, not four to six.

Does BPC-157's half-life justify twice-daily injections?

No measured half-life supports twice-daily BPC-157 injections. The twice-daily logic is coherent only if the 4 to 6 hour figure were real: space doses to avoid long gaps below an assumed effective concentration.

That logic needs two things nobody has: a documented human half-life, and evidence that the plasma concentration of intact BPC-157 tracks with the effect someone is trying to achieve. If BPC-157's plasma half-life is under 30 minutes, a twice-daily subcutaneous schedule built on a 4-hour assumption leaves detectable circulating peptide for a small fraction of the day, not the sustained coverage the schedule implies.

More frequent injection is not automatically correct either. No one has published a human dose-response or dose-frequency study from which to derive an evidence-based interval ^[6]. The dosing logic in vendor calculators and forum protocols was not built from the pharmacokinetic data that exist ^[7].

Dexrazoxane shows what a schedule built on measurement looks like. The chelating agent, used ahead of certain chemotherapy regimens, has a short plasma half-life that makes repeated bolus dosing an inefficient way to sustain exposure, so investigators measured its rapid clearance directly and designed a 96-hour continuous infusion around it ^[4]. Nothing comparable exists for BPC-157. A twice-daily schedule built on an untraceable number cannot be fixed by choosing a better interval, because the human measurement that would justify any interval has not been done.

Can BPC-157's effects outlast its time in the bloodstream?

Effects that outlast a molecule's time in the blood are documented for GLP-1 receptor agonists and growth hormone ^[1]⁠^[3], but no study has tested whether BPC-157 behaves the same way. Plasma clearance and downstream biological effect are separate measurements, and a receptor-level or tissue-level effect can outlast the triggering molecule's presence in blood.

Immediate intravenous infusion and weeks of ongoing dosing with GLP-1 receptor agonists produced measurably different effects on kidney handling of uric acid. Acute plasma presence and cumulative downstream effect are not interchangeable ^[1]. Growth hormone replacement shows a related pattern: sodium retention and fluid shifts measured after seven days differed from those measured after twelve months, even though circulating growth hormone clears on a much shorter timescale ^[3].

Local injection-site delivery of BPC-157 is sometimes defended on the same theory, that tissue-level, receptor-mediated signaling outlasts plasma presence. The idea is mechanistically plausible for a peptide acting locally rather than through sustained systemic concentration. It remains a hypothesis that neither the rat and dog pharmacokinetic study nor the translational review confirms ^[7]⁠^[6]. A separate analysis traces where local BPC-157 injection protocols come from.

What is still unknown about BPC-157's pharmacokinetics?

BPC-157's human half-life, the right concentration to track, and the duration of any effect are all unmeasured:

• Human half-life. No published study has measured BPC-157 clearance in people, by any route.
• What to measure. Whether the plasma concentration of intact BPC-157 is the right thing to track at all is unresolved.
• Effect duration. How long any downstream effect lasts, the question that matters for dosing, has not been measured.
• Dosing interval. No human dose-response or dose-frequency study exists to set an interval ^[6].

Animal pharmacokinetic data point to fast clearance of the intact molecule ^[7]. No human clearance study exists, and every human half-life figure in circulation, including 4 to 6 hours, is extrapolation.